- Created on the 13 July, 2017.
Chagas disease is known to occur predominately in the continental part of Latin America and it is a life threatening illness that is caused by the protozoan parasite known as Trypanosoma cruzi (T. cruzi). It is estimated that around 6-7 million people worldwide are infected by this parasite, it is mainly vector borne transmitted by either contact with urine or faeces of triatomine bugs. The Chagas disease is presents itself in 2 phases. The initial acute phase (lasts two months). Where there is a high number of parasites which are circulating in the blood but the symptoms are often absent or mild and also non-specific. The second chronic phase, where the parasite is located in the digestive muscles and heart. This leads to cardiac disorders, digestive disorders (typically enlarged oesophagus and colon), neurological and many other mixed alterations. In the later years the infection can cause sudden death due to cardiac arrhythmias or heart failure because of the constant destruction of the heart muscle and the nervous system.
Human Chagas IgG ELISA kit can be used for analysing in-vitro quantitative concentrations of IgG antibodies to Chagas (Trypanosoma cruzi) in human serum and plasma samples. This assay has a minimum analytical sensitivity limit to a diagn. 99%.
The minimum detection sensitivity level of human Chagas (Trypanosoma cruzi, T. cruzi) IgG using this human Chagas IgG ELISA kit was diagn. 99%. The dynamic assay range for this kit was to a specific cut-off point.
- IgG subclass reactivity to Trypanosoma cruziin chronic chagasic patients. Arch Cardiol Mex. (2001) 71 (3): 199-205. Hernández-Becerril N., et al.
- Dried blood as an alternative to plasma or serum for Trypanosoma cruzi IgG detection in screening programs. Clin Vaccine Immunol. (2013) 20 (8): 1197-202. Holguín A., et al.
- [Preliminary evaluation of the commercial kit Chagas (Trypanosoma cruzi) IgG-ELISA ® in Colombian individuals]. Biomedica. (2014) 34 (2): 228-36. Spanish. Llano M., et al.
- The use of IgG antibodies in conventional and non-conventional immunodiagnostic tests for early prognosis after treatment of Chagasdisease. J Immunol Methods. (2011) 370 (1-2): 24-34. Wendling A.P., et al.
- In-house ELISA method to analyze anti-Trypanosoma cruzi IgG reactivity for differential diagnosis and evaluation of Chagas disease morbidity. Rev Soc Bras Med Trop. (2012) 45 (1): 35-44. Santos L da S., et al.
- Full Name: Chagas (Trypanosoma Cruzi) IgG ELISA Kit
- Reactivity: Human
- Sample Type: Plasma, Serum
- Sensitivity: diagn. 99%